www.hiv-druginteractions.org

UNIVERSITY OF LIVERPOOL

Interaction Report

Report ID:
Date Produced: 30 June 2025

Antiretroviral Treatment	Co-medications
Efavirenz (EFV) Emtricitabine (FTC) Tenofovir-DF (TDF)	Prednisone

This report lists the summaries of potential interactions (i.e. "red", "amber" and “yellow” classifications) for the drugs in the table above.

Interactions with a "green" or "grey" classification (i.e. no clinically significant interaction or no clear data) have been checked and are listed at the end of this report, but summaries are not shown.

For full details of all interactions, see www.hiv-druginteractions.org .

Description of the interactions

Potential clinically significant interaction - likely to require additional monitoring, alteration of drug dosage or timing of administration (AMBER)

Efavirenz (EFV) + Prednisone
Prednisone is converted to the active metabolite prednisolone by 11-B-hydroxydehydrogenase. Prednisolone is then metabolized by CYP3A4. Pharmacokinetics of prednisolone were determined following administration of prednisone (20 mg single dose) in three groups of ten HIV+ subjects receiving either lopinavir/ritonavir or efavirenz or no antiretrovirals. Prednisolone AUC was 20% lower in the presence of efavirenz than in subjects on no antiretrovirals and was significantly lower (40% decrease) in the presence of efavirenz versus lopinavir/ritonavir. Prednisolone concentrations may fluctuate widely when patients on efavirenz switch to lopinavir/ritonavir or vice versa.

No clinically significant interaction expected (GREEN)

Emtricitabine (FTC) + Prednisone

Tenofovir-DF (TDF) + Prednisone